FDA offers guidance on labeling mutation risks of ingredients; Accuratus gets CMC operation;

> The FDA has issued guidance on the need for drugmakers to assess and label the risks of impurities in drugs to create DNA mutations that might lead to cancer. Guidance

> Accuratus Lab Services has acquired Array BioPharma's chemistry, manufacturing and controls (CMC) operation to expand its its CDMO services. Report

> An FDA advisory committee next month will evaluate post marketing studies of the use and abuse of the new abuse deterrent formulation of Oxycontin ER. Report

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)